Why Is Liver Disease Focused Tharimmune Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Tharimmune Inc (NASDAQ:THAR) has signed an exclusive worldwide licensing agreement with Avior Inc. to develop, market, and commercialize a clinical-stage asset, AV104 (to be renamed TH104). TH104 is aimed at treating chronic pruritis in patients with primary biliary cholangitis (PBC), an orphan liver disease. The company expects to complete a phase 1 pharmacokinetic trial and a phase 2 proof-of-concept efficacy study in PBC patients over approximately 12 months. Tharimmune's shares are up 37.50% at $0.22.
November 07, 2023 | 6:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tharimmune's stock is trading higher following the announcement of an exclusive licensing agreement with Avior for the development of TH104. The company's shares are up 37.50%.
The news of the exclusive licensing agreement with Avior for the development of TH104, a drug aimed at treating chronic pruritis in PBC patients, is a positive development for Tharimmune. This could potentially open up new revenue streams for the company, hence the increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100